

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES ISIS-1512 WO.US DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known see 37 CFR 1.5) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 28 November 2003 November 2004 PCT/GB2004/005019 TITLE OF INVENTION NOVEL USES OF KNOWN DRUGS APPLICANT(S) FOR DO/EO/US SEWELL. Andrew Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. X This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. X The US has been elected (Article 31). X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7. X Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter (unexecuted) A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

TO HECOPOTPIO 26 MAY 2005

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Not yet			PCT/GB2004/		ISIS-1512		
Other items or information: Copy of front page of published international application, publication No. WO 2005/053681 A2; Copy of PCT/IB/304; Copy of PCT/IB/308(First notice); Copy of PCT/IB/308(second notice)							
The following	fees have beer	CALCULATIONS	PTO USE ONLY				
21. 🙀 Basic nati	onal fee (37 CF	\$ 300					
If the written opinion p	dicates all claim	\$ 200					
If the written opinion of IPEA/US indic Search fee (37 CFR 1. International Search R	ates all claims s 445(a)(2)) has l Searching Autho eport prepared municated to th	\$ 400					
TOTAL OF 21, 22 and 23 =					900		
electronic med	specification and ng in compliance tium) (37 CFR 1 0 for each additi						
	Number of each additional 50 or fraction thereof (round up to a whole number)						
- 100 = Surcharge of \$130.00 after the date of comm	_	\$ 0					
CLAIMS NUMBER FILED		NUMBER EXTRA	RATE	\$			
Total claims	25	- 20 =	5	x \$ 50	\$ 250		
Independent claims	3	- 3 =	0	× \$200	\$ O		
MULTIPLE DEPENDE	NT CLAIM(S) (i	\$ O					
		\$ j150					
Applicant claims s	mall entity statu	1.7					
December 1840	0.00 for five in his	\$ 575.00					
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).							
		\$ 575.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$		
		\$ 575.00					
					Amount to be refunded:	\$	
					Amount to be charged	\$	

101583658 25 MAY 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a.	check in the amount of \$ to cover the above	e fees is enclosed.					
	Please charge my Deposit Account No. <u>503194</u> in the amount of \$ <u>575.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.						
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 503194. A duplicate copy of this sheet is enclosed.						
	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
Matthew Kaser Bell & Associates 416 Funston Ave., Ste. 100 San Francisco: CA 94118 Tel: \$510) 537-2040 Fax: (415) 276-6040		SIGNATURE Matthew Kaser NAME 44.817 REGISTRATION NUMBER					

Docket No.: ISIS-1512 WO US

'APPREC'OPTIPTO 26 MAY 2005

"Express Mail" mailing label number EQ 580509495 US
I hereby certify that this document and referenced attachments
are being deposited with the United States Postal Service "Express
Mail Post Office to Addressee" addressed to: Mail Stop PCT,
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on <u>26th May 2006</u>

Printed: Matthew R. Kaser Signed:

1000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. National Phase Application of: SEWELL, Andrew

Title: Novel Uses of Known Drugs

International application number:

PCT/GB2004/005019

International Filing Date:

29 November 2004

Priority application number:

GB0327742.3

P: 4 Filter Deter

20 None - - 1- - - 200

Priority Filing Date;

28 November 2003

To:

Mail Stop PCT Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Enclosed:

Return receipt postcard

Transmittal cover letter (1 page)

Transmittal Sheet PTO-1390 (3 pages, 3rd page in duplicate)

Preliminary Amendment (7 pages)

Copy of first page of published International Application (1 pages)

Copy of PCT/IB/304 (1 page)

Copy of PCT/IB/308 (2 pages)

Declaration, executed (2 pages)

Power of Attorney, unexecuted (1 page)

Respectfully submitted,

Matthew Kaser, D.Phil.

Reg. No. 44,817

Bell & Associates

416 Funston Avenue, Suite 100

San Francisco, California 94118

Tel: (510) 537-2040

Fax: (415) 276-6040

mkaser@bell-iplaw.com